Balan Marc D, Mcleod Matthew J, Lotosky William R, Ghaly Mark, Holyoak Todd
Department of Biochemistry and Molecular Biology, The University of Kansas Medical Center , Kansas City, Kansas 66160, United States.
Department of Biology, University of Waterloo , Waterloo, ON N2L 3G1, Canada.
Biochemistry. 2015 Sep 29;54(38):5878-87. doi: 10.1021/acs.biochem.5b00822. Epub 2015 Sep 11.
For almost 40 years, it has been known that tryptophan metabolites and picolinic acid analogues act as inhibitors of gluconeogenesis. Early studies observed that 3-mercaptopicolinic acid (MPA) was a potent hypoglycemic agent via inhibition of glucose synthesis through the specific inhibition of phosphoenolpyruvate carboxykinase (PEPCK) in the gluconeogenesis pathway. Despite prior kinetic investigation, the mechanism of the inhibition by MPA is unclear. To clarify the mechanism of inhibition exerted by MPA on PEPCK, we have undertaken structural and kinetic studies. The kinetic data in concert with crystallographic structures of PEPCK in complex with MPA and the substrates for the reaction illustrate that PEPCK is inhibited by the binding of MPA at two discrete binding sites: one acting in a competitive fashion with PEP/OAA (∼10 μM) and the other acting at a previously unidentified allosteric site (Ki ∼ 150 μM). The structural studies suggest that binding of MPA to the allosteric pocket stabilizes an altered conformation of the nucleotide-binding site that in turn reduces the affinity of the enzyme for the nucleotide.
近40年来,人们一直知道色氨酸代谢产物和吡啶甲酸类似物可作为糖异生的抑制剂。早期研究观察到,3-巯基吡啶甲酸(MPA)是一种强效降糖剂,它通过特异性抑制糖异生途径中的磷酸烯醇式丙酮酸羧激酶(PEPCK)来抑制葡萄糖合成。尽管之前进行了动力学研究,但MPA的抑制机制尚不清楚。为了阐明MPA对PEPCK的抑制机制,我们进行了结构和动力学研究。动力学数据与PEPCK与MPA及反应底物形成复合物的晶体结构相结合表明,PEPCK受到MPA在两个不同结合位点的结合抑制:一个以与磷酸烯醇式丙酮酸/草酰乙酸(约10 μM)竞争的方式起作用,另一个作用于先前未确定的变构位点(抑制常数Ki约为150 μM)。结构研究表明,MPA与变构口袋的结合稳定了核苷酸结合位点的改变构象,进而降低了酶对核苷酸的亲和力。